Risk Factors for Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study

被引:14
作者
Guo, Rong-Jing [1 ]
Gao, Ting [1 ]
Ruan, Zhe [1 ]
Zhou, Hong-Yu [2 ]
Gao, Feng [3 ]
Xu, Quan [4 ]
Yu, Li-Ping [5 ]
Wu, Song-Di [6 ]
Lei, Tao [7 ]
Li, Huan-Huan [1 ]
Sun, Chao [1 ]
Zhang, Min [1 ]
Gao, Yan-Wu [1 ]
Lu, Xiao-Dan [1 ]
Tang, Yong-Lan [1 ]
Tang, Bao-Li [1 ]
Huo, Fei-Yan [1 ]
Zhu, Ying [1 ]
Li, Zhu-Yi [1 ]
Chang, Ting [1 ]
机构
[1] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710038, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Peoples R China
[3] Zhengzhou Univ, Henan Inst Med & Pharmaceut Sci, Dept Neuroimmunol, Zhengzhou, Peoples R China
[4] Jiangxi Prov Peoples Hosp, Dept Thorac Surg, Nanchang, Jiangxi, Peoples R China
[5] Xianyang First Peoples Hosp, Dept Neurol, Xianyang, Peoples R China
[6] Xian 1 Hosp, Dept Neurol, Xian, Peoples R China
[7] Xian Fourth Hosp, Dept Neurol, Xian, Peoples R China
基金
中国国家自然科学基金;
关键词
Ocular myasthenia gravis; Generalized myasthenia gravis; Generalization; Risk factors; Cox proportional hazards model; PROGNOSIS;
D O I
10.1007/s40120-021-00292-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Many patients with ocular myasthenia gravis (OMG) progress to generalized disease within the first 2 years of the onset of ocular symptoms. Several retrospective studies have identified risk factors associated with generalization, however these studies included patients on immunosuppression therapy or those undergoing thymectomy, which may reduce the generalization risk. In this study we explored the risk factors for generalization in non-immunosuppressed and non-thymectomized patients with OMG. Methods Data from patients with OMG treated at seven tertiary hospitals in China were retrospectively reviewed. Clinical characteristics, including sex, age at onset, symptoms at onset, comorbid autoimmune diseases, neostigmine test response, repetitive nerve stimulation (RNS) findings, presence of serum anti-acetylcholine receptor antibody (AChR-Ab), and thymic status based on radiological and pathological studies, were collected. The main outcome measure was disease generalization. The follow-up period was defined as the date of ocular symptom onset to the date of confirmation of generalization or immunotherapy initiation, or last follow-up (defined as 60 months). The Cox proportional hazards model was used to assess the risk factors for generalization. Results Overall, 572 patients (269 women) were eligible for inclusion in the analysis, of whom 144 developed generalization. The mean (standard deviation) onset age was 45.5 (19.8) years, and the median (interquartile range) follow-up period was 14.5 (7.0-47.3) months. Multivariable Cox regression analysis demonstrated that both early-onset (adjusted hazard ratio [aHR] 5.34; 95% confidence interval [CI] 1.64-17.36; p = 0.005) and late-onset (aHR 7.18; 95% CI 2.22-23.27; p = 0.001) in adulthood, abnormal RNS findings (aHR 3.01; 95% CI 1.97-4.61; p < 0.001), seropositivity for AChR-Ab (aHR 2.58; 95% CI 1.26-5.26; p = 0.01), and thymoma (aHR 1.62; 95% CI 1.05-2.49; p = 0.03) were independently associated with increased risk of generalization. Conclusion The risk of generalization increased significantly in patients with adult-onset OMG, abnormal RNS findings, seropositivity for AChR-Ab, and thymoma, suggesting that these risk factors may predict OMG generalization.
引用
收藏
页码:73 / 86
页数:14
相关论文
共 37 条
[1]   Prognosis of Ocular Myasthenia Gravis in an Argentinian Population [J].
Aguirre, Florencia ;
Villa, Andres M. .
EUROPEAN NEUROLOGY, 2018, 79 (3-4) :113-117
[2]   Ocular Myasthenia [J].
Al-Haidar, Mohammed ;
Benatar, Michael ;
Kaminski, Henry J. .
NEUROLOGIC CLINICS, 2018, 36 (02) :241-+
[3]   OCULAR MYASTHENIA GRAVIS IN A SENIOR POPULATION: DIAGNOSIS, THERAPY, AND PROGNOSIS [J].
Allen, Jeffrey A. ;
Scala, Stephanie ;
Jones, H. Royden .
MUSCLE & NERVE, 2010, 41 (03) :379-384
[4]   Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody [J].
Apinyawasisuk, Supanut ;
Chongpison, Yuda ;
Thitisaksakul, Chawin ;
Jariyakosol, Supharat .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2020, 209 :10-17
[5]   PROGNOSIS OF OCULAR MYASTHENIA [J].
BEVER, CT ;
AQUINO, AV ;
PENN, AS ;
LOVELACE, RE ;
ROWLAND, LP .
ANNALS OF NEUROLOGY, 1983, 14 (05) :516-519
[6]   Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study [J].
Chen, Jingshan ;
Tian, De-Cai ;
Zhang, Chao ;
Li, Zixiao ;
Zhai, Yi ;
Xiu, Yuwen ;
Gu, Hongqiu ;
Li, Hao ;
Wang, Yongjun ;
Shi, Fu-Dong .
LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2020, 5
[7]   Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China [J].
Ding, Jiaqi ;
Zhao, Sijia ;
Ren, Kaixi ;
Dang, Dan ;
Li, Hongzeng ;
Wu, Fang ;
Zhang, Min ;
Li, Zhuyi ;
Guo, Jun .
BMC NEUROLOGY, 2020, 20 (01)
[8]   Acquired myasthenia gravis in childhood [J].
Evoli, Amelia .
CURRENT OPINION IN NEUROLOGY, 2010, 23 (05) :536-540
[9]   Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China [J].
Feng, Xuelin ;
Huan, Xiao ;
Yan, Chong ;
Song, Jie ;
Lu, Jun ;
Zhou, Lei ;
Wu, Hui ;
Qiao, Kai ;
Lu, Jiahong ;
Xi, Jianying ;
Luo, Sushan ;
Zhao, Chongbo .
EUROPEAN NEUROLOGY, 2020, 83 (02) :182-188
[10]   Antibody profile may predict outcome in ocular myasthenia gravis [J].
Galassi, Giuliana ;
Mazzoli, Marco ;
Ariatti, Alessandra ;
Kaleci, Shaniko ;
Valzania, Franco ;
Nichelli, Paolo F. .
ACTA NEUROLOGICA BELGICA, 2018, 118 (03) :435-443